Contineum's Lead Depression Drug Fails Phase 2, Shares Plunge
CTNM sits 55% above its 52-week low of $8.6.
Summary
Contineum's partnered lead asset JNJ-5120/PIPE-307 failed its Phase 2 primary efficacy endpoint in major depressive disorder. This is a major setback for the company's most advanced program, developed with Johnson & Johnson. The failure likely removes a key near-term value driver and raises questions about the broader pipeline. The 8-K filed earlier today confirms the trial miss; this Reuters report adds market reaction and context. Watch for management commentary on next steps and any impact on the J&J partnership.
At the time of this announcement, CTNM was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.5M. The 52-week trading range was $8.60 to $17.79. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.